These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 23392469)

  • 41. Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
    van Lelyveld SF; Drylewicz J; Krikke M; Veel EM; Otto SA; Richter C; Soetekouw R; Prins JM; Brinkman K; Mulder JW; Kroon F; Middel A; Symons J; Wensing AM; Nijhuis M; Borghans JA; Tesselaar K; Hoepelman AI;
    PLoS One; 2015; 10(7):e0132430. PubMed ID: 26208341
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
    Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
    Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs.
    Fraser C; Ferguson NM; Ghani AC; Prins JM; Lange JM; Goudsmit J; Anderson RM; de Wolf F
    AIDS; 2000 Apr; 14(6):659-69. PubMed ID: 10807189
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Delay in cART initiation results in persistent immune dysregulation and poor recovery of T-cell phenotype despite a decade of successful HIV suppression.
    Ndumbi P; Falutz J; Pant Pai N; Tsoukas CM
    PLoS One; 2014; 9(4):e94018. PubMed ID: 24710051
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune reconstitution in HIV+ subjects on lopinavir/ritonavir-based HAART according to the severity of pre-therapy CD4+.
    Marchetti G; Merlini E; Sinigaglia E; Iannotti N; Bai F; Savoldi A; Tincati C; Carpani G; Bini T; Arminio Monforte A
    Curr HIV Res; 2012 Oct; 10(7):597-605. PubMed ID: 22716104
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years.
    Arnó A; Ruiz L; Juan M; Zayat MK; Puig T; Balagué M; Romeu J; Pujol R; O'Brien WA; Clotet B
    AIDS; 1998 May; 12(7):697-704. PubMed ID: 9619800
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of immune complexes and plasma viral load with CD4+ cell depletion, CD8+ DR+ and CD16+ cell counts in HIV+ hemophilia patients. Implications for the immunopathogenesis of HIV-induced CD4+ lymphocyte depletion.
    Daniel V; Süsal C; Weimer R; Zimmermann R; Huth-Kühne A; Opelz G
    Immunol Lett; 2001 Mar; 76(2):69-78. PubMed ID: 11274723
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of T cell activation, HIV replication and hepatitis C virus infection on neutrophil CD64 expression.
    Morquin D; Tuaillon E; Makinson A; Bendriss S; Le Moing V; Reynes J
    Cytometry B Clin Cytom; 2017 Nov; 92(6):492-497. PubMed ID: 27221825
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prolonged Antiretroviral Therapy in Adolescents With Vertical HIV Infection Leads to Different Cytokine Profiles Depending on Viremia Persistence.
    Munhoz LGC; Garcia Spina F; Machado DM; Gouvea A; Succi RCM; Diaz RS; De Moraes-Pinto MI
    Pediatr Infect Dis J; 2019 Nov; 38(11):1115-1120. PubMed ID: 31626046
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD4+ and CD8+ T cell receptor repertoire perturbations with normal levels of T cell receptor excision circles in HIV-infected, therapy-naive adolescents.
    Pahwa S; Chitnis V; Mitchell RM; Fernandez S; Chandrasekharan A; Wilson CM; Douglas SD
    AIDS Res Hum Retroviruses; 2003 Jun; 19(6):487-95. PubMed ID: 12882658
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors.
    Plana M; Martínez C; García F; Maleno MJ; Barceló JJ; García A; Lejeune M; Vidal C; Cruceta A; Miró JM; Pumarola T; Gallart T; Gatell JM
    J Acquir Immune Defic Syndr; 2002 Apr; 29(5):429-34. PubMed ID: 11981357
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CXCL13 as a Biomarker of Immune Activation During Early and Chronic HIV Infection.
    Mehraj V; Ramendra R; Isnard S; Dupuy FP; Lebouché B; Costiniuk C; Thomas R; Szabo J; Baril JG; Trottier B; Coté P; LeBlanc R; Durand M; Chartrand-Lefebvre C; Kema I; Zhang Y; Finkelman M; Tremblay C; Routy JP
    Front Immunol; 2019; 10():289. PubMed ID: 30846990
    [No Abstract]   [Full Text] [Related]  

  • 54. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
    Stone SF; Price P; French MA
    HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characteristics and determinants of T-cell phenotype normalization in HIV-1-infected individuals receiving long-term antiretroviral therapy.
    Ndumbi P; Gillis J; Raboud J; Cooper C; Hogg RS; Montaner JS; Burchell AN; Loutfy MR; Machouf N; Klein MB; Tsoukas C;
    HIV Med; 2014 Mar; 15(3):153-64. PubMed ID: 24304582
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover.
    Anthony KB; Yoder C; Metcalf JA; DerSimonian R; Orenstein JM; Stevens RA; Falloon J; Polis MA; Lane HC; Sereti I
    J Acquir Immune Defic Syndr; 2003 Jun; 33(2):125-33. PubMed ID: 12794543
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
    Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
    Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy.
    Lim A; Tan D; Price P; Kamarulzaman A; Tan HY; James I; French MA
    AIDS; 2007 Jul; 21(12):1525-34. PubMed ID: 17630546
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
    García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
    AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterizing the immune system after long-term undetectable viral load in HIV-1-infected children.
    Resino S; Galán I; Bellón JM; Navarro ML; León JA; Muñoz-Fernandez MA
    J Clin Immunol; 2003 Jul; 23(4):279-89. PubMed ID: 12959220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.